Quanterix Taps Diagnostics Veteran to Lead Alzheimer’s Testing Push
Event summary
- Quanterix appointed Geoff Albrecht as SVP and GM of Diagnostics, effective June 2026.
- Albrecht brings 25 years of experience from Quest Diagnostics, including $2.9B revenue oversight.
- He will lead Quanterix’s Alzheimer’s diagnostics strategy and scale its diagnostics portfolio.
- Albrecht reports directly to CEO Everett Cunningham and joins the Executive Leadership Team.
The big picture
Quanterix’s appointment of Geoff Albrecht signals a strategic pivot toward diagnostics, particularly in Alzheimer’s testing. This move aligns with broader industry trends toward precision medicine and biomarker-driven diagnostics. With the acquisition of Akoya Biosciences, Quanterix is positioning itself as a leader in connecting blood and tissue biology for diagnostic purposes. The success of this strategy will depend on Albrecht’s ability to scale the diagnostics portfolio and drive revenue growth.
What we're watching
- Diagnostics Growth
- Whether Quanterix can successfully transform its diagnostics business into a significant revenue driver.
- Alzheimer’s Focus
- How Albrecht’s experience will impact Quanterix’s ability to penetrate the Alzheimer’s diagnostics market.
- Integration Success
- The pace at which Quanterix integrates its recent acquisitions to enhance its diagnostics and spatial biology offerings.